Articles From: Ignore copper and mind the Swiss as jobs bring focus back to the U.S. to IGT Wheel Of Fortune® Spins $1.6 Million Jackpot To Lucky Player At The Venetian Las Vegas


2014/12/5
By Shawn Langlois, MarketWatch Critical intelligence before the U.S. market opens At one point late Thursday, the two most popular stories on MarketWatch were in direct conflict.
Sign-up for Ignore copper and mind the Swiss as jobs bring focus back to the U.S. investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its San Diego diagnostic laboratory successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification.
Sign-up for Ignyta Announces CLIA Certification Achieved by its Diagnostic Laboratory investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.
Sign-up for Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Sign-up for Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR ‘Molecular Targets and Cancer Therapeutics’ Conference investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2014.
Sign-up for Ignyta Announces Third Quarter 2014 Company Highlights and Financial Results investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “entrectinib” for the company’s lead product candidate, RXDX-101.
Sign-up for Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101 investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it has secured a $31 million term loan facility from Silicon Valley Bank.
Sign-up for Ignyta Secures $31 Million Term Loan Facility from Silicon Valley Bank investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chief Medical Officer, Adrian Senderowicz, M.D., has been selected to serve as Workshop Planning Committee Chair for the workshop entitled Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer .
Sign-up for Ignyta to Chair the Institute of Medicine’s National Cancer Policy Forum Workshop on Molecularly Targeted Cancer Therapies investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it will host a Key Opinion Leader Breakfast on Tuesday, October 14, 2014 from 8:00-9:30 a.m. Eastern time in New York City.
Sign-up for Ignyta to Host Investor Meeting with Oncology Key Opinion Leaders on October 14, 2014 investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
Sign-up for Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Jacob Chacko, M.D., Chief Financial Officer, will make a presentation at the Livingston Securities Life Science Stakeholders Summit on October 1, 2014 at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) in Philadelphia, PA.
Sign-up for Ignyta to Present at Livingston Securities Life Science Stakeholders Summit investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that its management will be making company presentations at the following investor conferences in December 2014: A webcast of each presentation will be available during the event in the Investors section of the company's website at http://investor.ignyta.com , and will be archived and available at that site for 14 days.
Sign-up for Ignyta to Present at Upcoming Investor Conferences investment picks
Ignyta, Inc. (Nasdaq: RXDX), an precision oncology biotechnology company, announced today that it will release its third quarter 2014 financial results after the market closes on Friday, November 7, 2014.
Sign-up for Ignyta to Report 2014 Third Quarter Company Highlights and Financial Results and Host Conference Call on November 7, 2014 investment picks
LAS VEGAS , Sept.
Sign-up for IGT and GTECH Amend Merger Agreement investment picks
Central Florida's Premier Entertainment Destination First to Showcase IGT's Sizzling S3000 LAS VEGAS , Nov.
Sign-up for IGT and Seminole Hard Rock Hotel & Casino Tampa Light Up the Gaming World with S3000 Cabinet investment picks
2014/10/8
LAS VEGAS , Oct.
Sign-up for IGT Announces Consent Solicitation for $1.3 Billion of Notes Due 2019, 2020 and 2023 investment picks
LAS VEGAS , Sept.
Sign-up for IGT Expands Jackpot Legacy with MegaHits in Maryland investment picks
LAS VEGAS , Sept.
Sign-up for IGT Lights Up Las Vegas At G2E 2014 investment picks
LAS VEGAS , Dec.
Sign-up for IGT Megabucks Pays Out Huge $14 Million Jackpot investment picks
Fiscal 2014 Results (compared to last year) - Total revenue decreased 12% to $2.1 billion - Social gaming revenue increased 28% to $281 million and average bookings per daily active user grew 16% to $0.43 - Adjusted earnings per share decreased 14% to $1.09 - GAAP earnings per share decreased 4% to $0.99 - Returned $319 million to shareholders in the form of share repurchases and dividends Fourth Quarter Results (compared to last year's fourth quarter) - Total revenue decreased 15% to $537 million - Social gaming revenue increased 22% to $75 million and average bookings per daily active user grew 15% to $0.46 - Adjusted earnings per share increased 23% to $0.37 - GAAP earnings per share increased 17% to $0.28 LAS VEGAS , Nov.
Sign-up for IGT Reports Fourth Quarter and Fiscal Year 2014 Results investment picks
LAS VEGAS , Sept.
Sign-up for IGT Systems Connect Players to Excitement at City of Dreams Manila investment picks
LAS VEGAS , Oct.
Sign-up for IGT Systems Fuel Market Leadership at Grand Casinos investment picks
LAS VEGAS , Sept.
Sign-up for IGT Wheel Of Fortune® Sparks $1.3 Million Jackpot At Firekeepers Casino investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Ignore copper and mind the Swiss as jobs bring focus back to the U.S. to IGT Wheel Of Fortune® Spins $1.6 Million Jackpot To Lucky Player At The Venetian Las Vegas
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent